Results 41 to 50 of about 18,875 (173)
Journal of Cosmetic Dermatology, 2023 To the Editor, The interesting article by Topal et al.1 about the cutaneous manifestations following COVID19 vaccination, which was recently published in your journal, prompted us to make some observations.
G. Ciccarese +3 more
semanticscholar +1 more source
Pityriasis Rosea Variant: Persistent Pityriasis Rosea in a 78-Year-Old Female Patient
Annals of Internal Medicine: Clinical Cases, 2023 Pityriasis rosea (PR) is a papulosquamous dermatosis seen most commonly in children and young adults. Variants of PR occur in 1 in 5 cases and can significantly impact a patient's quality of life.
Evelyn Fagan +3 more
doaj +1 more source
Pityriasis Rosea of Gibert: A Comprehensive Review of a Common, Self-Limiting Dermatologic Entity
International Journal of Medical Science and Clinical Research Studies, 2023 Pityriasis rosea of Gibert is a common, self-limiting dermatologic entity that continues to raise questions regarding its etiology, diagnosis, and clinical management.
Monserrat Espinosa Ramos +2 more
semanticscholar +1 more source
Pityriasis Rosea Recurrence is Much Higher than Previously Known: A Prospective Study
Acta Dermato-Venereologica, 2019 Pityriasis rosea is a common acute exanthema of unknown aetiology, which causes severe anxiety. In this study, the demographic data of pityriasis rosea patients, who presented to our clinic between 2013 and 2017, were prospectively recorded. The patients
Mavişe Yüksel
doaj +1 more source
Pityriasis Rosea in a Woman and Her Husband – Case Report and Review of the Literature
Case Reports in Dermatology, 2010 Pityriasis rosea is an acute, self-limited papulosquamous dermatosis of the trunk and extremities. Many atypical forms of the disease have been reported in the literature [Ahmed et al.: Clin Exp Dermatol 2000;25:624–626; Imamura et al.: Dermatologica ...
Natalya Lemster +2 more
doaj +1 more source
Levetiracetam-induced Pityriasis rosea: A rare case report
Indian Journal of Drugs in Dermatology, 2023 Levetiracetam is a second-generation anti-epileptic drug (AED). It is generally considered to be a safer alternative as compared to the first-generation AEDs with lesser side effects and no cross-reactivity. Many cutaneous adverse events to Levetiracetam
Siddharth Bhatt +3 more
semanticscholar +1 more source
Journal of the Formosan Medical Association = Taiwan yi zhi, 2022 Pityriasis rosea (PR) is a self-limited disease with exanthematous papulosquamous rashes mostly associated with reactivation of human herpesvirus (HHV)-6 or HHV-7.
Chii-Shyan Wang +2 more
semanticscholar +1 more source
Subsets of T lymphocytes in the lesional skin of pityriasis rosea [PDF]
Anais Brasileiros de Dermatologia: Background: Pityriasis rosea is a common papulosquamous disorder. However, its etiology and pathogenesis remain unclear. Objective: We investigate the types of inflammatory cells infiltrating the lesional skin of pityriasis rosea and demonstrate ...
Shuqin Wang +5 more
doaj +2 more sources
Atypical pityriasis rosea in a young Colombian woman. Case report
Case Reports, 2021 Introduction: Pityriasis rosea is an acute and self-limited exanthem first described by Gilbert in 1860. Its treatment is symptomatic, and although there is no conclusive evidence, it has been associated with the reactivation of the human herpesviruses ...
Julián Felipe Porras-Villamil +3 more
doaj +1 more source
Pityriasis rosea, COVID‐19 and vaccination: new keys to understand an old acquaintance
Journal of the European Academy of Dermatology and Venereology, 2021 Lately we have witnessed sporadic reports of Pityriasis Rosea (PR) and PR-like eruptions associated with SARS-CoV-2. Such relationship has raised debate on the possible etiopathogenic mechanism underlying this exanthematous disease.
J.M. Busto‐Leis +7 more
semanticscholar +1 more source